Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites

Hepatology Research

Volumn 41, Issue 11, 2011, Pages 1017-1024

  Deng, Lihui ^a,b   Tang, Hong ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Chronic hepatitis B; Drug resistance; Hepatitis B virus; Nucleos(t)ide analogs

Indexed keywords

ADEFOVIR DIPIVOXIL; CIRCULAR DNA; CLEVUDINE; EMTRICITABINE; ENTECAVIR; ENZYME INHIBITOR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; LEVO DEOXYTHYMIDINE; NUCLEOSIDE ANALOG; NUCLEOTIDYLTRANSFERASE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANTIVIRAL THERAPY; CHRONIC HEPATITIS; CROSS RESISTANCE; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME POLYMORPHISM; GENE MUTATION; GENETIC VARIABILITY; HEPATITIS B; HOST; HUMAN; IMMUNE RESPONSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS GENOME; VIRUS MORPHOLOGY; VIRUS REPLICATION; VIRUS STRAIN;

EID: 84861141605     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00873.x     Document Type: Review

References (67)

1. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-75.
2. Lok AS, Zoulim F, Locarnini S et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46: 254-65.
3. Holomán J, Glasa J. EASL clinical practice guidelines. J Hepatol 2009; 51: 821-2.
4. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
5. Stuyver LJ, Locarnini SA, Lok A et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33: 751-7.
6. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137: 1593-608.
7. Tillmann HL. Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol 2007; 13 (1): 125-40.
8. Locarnini S, Bowden S. Drug resistance in antiviral therapy. Clin Liver Dis 2010; 14 (3): 439-59.
9. Zhou T, Saputelli J, Aldrich CE, Deslauriers M, Condreay LD, Mason WS. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Antimicrob Agents Chemother 1999; 43: 1947-54.
10. Werle-Lapostolle B, Bowden S, Locarnini S et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-8.
11. Amini-Bavil-Olyaee S, Vucur M, Luedde T, Trautwein C, Tacke F. Differential impact of immune escape mutations G145R and P120T on the replication of lamivudineresistant hepatitis B virus e antigen-positive and -negative strains. J Virol 2010; 84: 1026-33.
12. Sheldon J, Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother 2008; 61: 766-8.
13. Sloan RD, Ijaz S, Moore PL, Harrison TJ, Teo CG, Tedder RS. Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant. Antivir Ther 2008; 13: 439-47.
14. Bartholomeusz A, Tehan BG, Chalmers DK. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir Ther 2004; 9: 149-60.
15. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine resistant mutants during prolonged lamivudine therapy. Hepatology 2000; 31: 1318-26.
16. Angus P, Vaughan R, Xiong S et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292-7.
17. Bartholomeusz A, Locarmini S, Ayves A et al. Molecular modelling of hepatitis B virus polymerase and Adefovir resistance identifies three clusters of mutations. Hepatology 2004; 40: 246A.
18. Bartholomeusz A, Locarmini S, Ayves A et al. Mechanistic basis for hepatitis B virus resistance to acyclic nucleoside phosphonate analogues, Adefovir and Tenofovir. Hepatology 2005; 42: 594A.
19. Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006; 26: 162-70.
20. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 2004; 64: 1-15.
21. Lai CL, Dienstag J, Schiff E et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-96.
22. Lok AS, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-22.
23. Tenney DJ, Levine SM, Rose RE et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004; 48: 3498-507.
24. Ono SK, Kato N, Shiratori Y et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001; 107: 449-55.
25. Allen MI, Deslauriers M, Andrews CW et al. Identification and characterisation of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 1670-7.
26. Ling R, Mutimer D, Ahmed M et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711-13.
27. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714-17.
28. Delaney WE IV, Yang H, Westland CE et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003; 77: 11833-41.
29. Nakanishi H, Kurosaki M, Asahina Y et al. Polymerase domain B mutation is associated with hepatitis relapse during long-term lamivudine therapy for chronic hepatitis B. Intervirology 2005; 48: 381-8.
30. Pai SB, Bozdayi AM, Pai RB et al. Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy. Antimicrob Agents Chemother 2005; 49: 2618-24.
31. Yatsuji H, Noguchi C, Hiraga N et al. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother 2006; 50: 3867-74.
32. Fu L, Cheng YC. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L (K) SddC (3TC) resistance. Biochem Pharmacol 1998; 55: 1567-72.
33. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27: 628-33.
34. Ogata N, Fujii K, Takigawa S, Nomoto M, Ichida T, Asakura H. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. J Med Virol 1999; 59: 270-6.
35. Warner N, Locarnini S, Kuiper M et al. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother 2007; 51: 2285-92.
36. Westland CE, Yang H, Delaney WE et al. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J Viral Hepat 2005; 12: 67-73.
37. Westland C, Delaney WT, Yang H et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology 2003; 125: 107-16.
38. Yuen MF, Lai CL. Adefovir dipivoxil in chronic hepatitis B infection. Expert Opin Pharmacother 2004; 5: 2361-7.
39. Lacombe K, Ollivet A, Gozlan J et al. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B viurs-co-infected patient. AIDS 2006; 20: 1-3.
40. Villeneuve JP, Durantel D, Durantel S et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39: 1085-9.
41. Fung SK, Andreone P, Han SH et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005; 43: 937-43.
42. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 2673-81.
43. Schildgen O, Sirma H, Funk A et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006; 354: 1807-12.
44. Curtis M, Zhu Y, Borroto-Esoda K. Hepatitis B virus containing the I233V mutation in the polymerase reversetranscriptase domain remains sensitive to inhibition by adefovir. J Infect Dis 2007; 196: 1483-6.
45. Villet S, Pichoud C, Trepo C et al. Selection of the A181T/V substitution in HBV chronically infected patients who developed a resistance to lamivudine and/ or adefovir. Hepatology 2006; 44: 555A.
46. Lee Y-S, Chung Y-H, Ryu SH et al. Hepatitis B virus with rtL80V/I mutation associates with poor response to adefovir dipivoxil therapy (Abstract 965). Hepatology 2005; 42: 575A.
47. Locarnini S, Qi X, Arerburn S et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV therapy for patients with chronic hepatitis B (CHB). J Hepatol 2005; 42: A36.
48. Tenney DJ, Rose RE, Baldick CJ et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-14.
49. Villet S, Ollivet A, Pichoud C et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007; 46: 531-8.
50. Warner N, Locarnini SA, Colledge D et al. Molecular modeling of entecavir resistant mutations in the hepatitis B virus polymerase selected during therapy. Hepatology 2003; 40: 245A.
51. Tenney DJ, Oliver AJ, Rose RE et al. Hepatitis B virus resistance to entecavir in volves novel changes in the viral polymerase. Hepatology 2003; 40: 245A.
52. Colonno R, Rose R, Levine S et al. Entecavir two year resistance update: no resistance observed in nucleoside naive patients and low frequency resistance emergence in lamivudine refractory patients (Abstract 962). Hepatology 2005; 42: 573A.
53. Yim HJ, Hussain M, Liu Y, Wong SN, Fung S, Lok A. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44: 703-12.
54. Lai CL, Gane E, Liaw YF et al. Globe Study Group. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-95.
55. Ladner S, Miller T, Otto M, King R. The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues. Antivir Chem Chemother 1998; 9: 65-72.
56. Chin R, Shaw T, Torresi J et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2, 6-diaminopurine dioxolane and 2-fluoro-5-methyl-beta-Larabinofuranosyluracil. Antimicrob Agents Chemother 2001; 45: 2495-501.
57. Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in H BV as a consequence of treatment failure. Hepatol Int 2008; 2: 147-51.
58. Sheldon J, Camino N, Rodes B et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10: 727-34.
59. Audsley J, Arrifin N, Yuen LK et al. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations. HIV Med 2009; 10: 229-35.
60. Gish RG. Clinical trial results of new therapies for HBV: implications for treatment guidelines. Semin Liver Dis 2005; 25: 29-39.
61. Locarnini S, Warner N. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV. Antivir Ther 2007; 12: H15-23.
62. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WET. Crossresistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10: 625-33.
63. Choe WH, Hong SP, Kim BK et al. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir. Antivir Ther 2009; 14: 985-93.
64. Brunelle MN, Jacquard AC, Pichoud C et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41: 1391-8.
65. Villet S, Pichoud C, Villeneuve JP et al. Selection of a multiple drug-resistant hepatitis B virus strain in a livertransplanted patient. Gastroenterology 2006; 131: 1253-61.
66. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008; 48: 88-98.
67. Villet S, Pichoud C, Billioud G et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008; 48: 747-55.